A clinical study reveals talquetamab's effectiveness as a bridging therapy before CAR T-cell treatment for multiple myeloma, enhancing patient outcomes.
Videos
Researchers explore talquetamab as a bridge therapy for multiple myeloma patients before CAR T-cell treatment, assessing safety and efficacy outcomes.
Experts explore innovative bridging therapies for multiple myeloma, enhancing patient outcomes before CAR T-cell treatment while addressing significant challenges.
Panelist discusses how the landmark ACCORD 11 trial established FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) as superior to gemcitabine for fit, young patients, whereas the MPACT trial demonstrated that gemcitabine plus nab-paclitaxel provided a more tolerable option for older patients with less preserved performance status.
Panelist discusses how CA 19-9 serves as a useful tumor marker for disease monitoring and recurrence detection in patients with pancreatic cancer, though it requires normalization of bilirubin levels for accurate baseline assessment.
IMA203 showed an excellent safety profile and promising efficacy in solid tumors, leading to a new registration-directed clinical trial.
A panelist discusses how first-line treatment for metastatic pancreatic cancer depends on performance status. ECOG 0-1 patients receive preferred options like FOLFIRINOX, modified FOLFIRINOX, or the newly FDA-approved NALIRIFOX regimen (which includes liposomal irinotecan for enhanced drug delivery), whereas ECOG 2 patients typically receive gemcitabine plus nab-paclitaxel, and ECOG 3 patients receive palliative care.
A panelist discusses how a man aged 82 years with good performance status presented with unexplained weight loss and abdominal pain, leading to a diagnosis of metastatic pancreatic adenocarcinoma with KRAS G12D and TP53 mutations confirmed through imaging, biopsy, and next-generation sequencing (NGS) testing.
Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.
Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.
Abhinav Agrawal, MD, discusses findings from a multidisciplinary expert panel on endoscopic lung and lymph node biopsies that show how changes in biopsy methods have affected comprehensive biomarker testing in lung cancer.
A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.
New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.
Guillermo Garcia-Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic syndrome.
Panelist discusses how genetic testing is recommended for all patients with pancreatic adenocarcinoma at diagnosis, including both germline testing for hereditary cancer syndromes and tumor profiling using next-generation sequencing (NGS) assays to identify actionable mutations.
Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a case of a 58-year-old patient with locally advanced disease and reviewing National Comprehensive Cancer Network treatment guidelines that mirror metastatic disease approaches.
Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.
Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment choices.
Without head-to-head trials, doctors balance MAIC efficacy data with factors like cost and safety to choose the best ARPI for each patient.
A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.
With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.
Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient survival rates.
An expert discusses the evolving landscape of large B-cell lymphoma (LBCL) treatment, highlighting emerging CAR T-cell targets and bispecific antibody strategies, the potential shift toward more personalized, less toxic therapies, and the ongoing challenges of improving patient access, referral, and posttreatment management to maximize outcomes.
An expert discusses the emerging role of bispecific antibodies in lymphoma treatment, highlighting their expanding use across treatment lines—including as alternatives or bridges to CAR T-cell therapy—their promising efficacy, more manageable toxicity profiles, and potential to improve patient quality of life through flexible care models.
An expert discusses the advances in managing CAR T-cell therapy toxicities, emphasizing aggressive early treatment of acute complications, the importance of coordinated long-term monitoring with community providers, and how real-world data validate the therapy’s safety and effectiveness across diverse patient populations.
Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.
Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.
Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.
An expert highlights how optimizing CAR T-cell therapy requires simplifying the treatment process, reducing insurance delays, addressing that 40% to 50% of patients may need further therapy, managing long-term immune and safety concerns, investigating risks like second malignancies, and enhancing collaboration between treatment centers and local providers to improve patient experience and outcomes.
An expert explains that T-cell fitness is critical for CAR T-cell therapy success, as earlier use—before multiple rounds of chemotherapy or bispecific antibody exposure—helps preserve T-cell quality and function, thereby improving response rates and long-term outcomes; consequently, early referral for CAR T is recommended to optimize treatment effectiveness.